A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a <sup>14</sup> C‐Microtracer Approach-Reference-Cited by-同舟云学术

A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a ¹⁴ C‐Microtracer Approach

Published:2022-05-04 Issue:7 Volume:11 Page:815-825
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Singh Ravi Shankar P.¹,Dowty Martin E.¹,Salganik Mikhail¹,Brodfuehrer Joanne I.¹,Walker Gregory S.²,Sharma Raman²,Beebe Jean S.¹,Danto Spencer I.¹

Affiliation:

1. Pfizer Inc Cambridge Massachusetts USA

2. Pfizer Inc Groton Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1109

Reference13 articles.

1. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

2. ClinicalTrials.govA study to evaluate the safety and efficacy of PF‐06650833 PF‐06700841 and PF‐06826647 in adults with hidradenitis suppurativa. Available at:https://clinicaltrials.gov/ct2/show/study/NCT04092452

3. Efficacy and safety of the selective interleukin‐1 receptor associated kinase 4 inhibitor, PF‐06650833, in patients with active rheumatoid arthritis and inadequate response to methotrexate [abstract 2909];Danto SI;Arthritis Rheumatol,2019

4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

5. What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer;Acta Pharmaceutica Sinica B;2024-09

2. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update;Biomedicines;2024-01-09

3. Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues;Small;2023-09-13